Loading stock data…
Ocugen, Inc. (OCGN)
$1.33-0.03 (-2.21%)
Market ClosedLast close Sep 8
Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Ocugen, Inc. in the Healthcare sector is trading at $1.33 with a market capitalization of $458M. Wall Street consensus targets $12.17 (6 analysts), implying a +814.8% move over the next 12 months. The stock is currently near its 52-week low of $1.03, remaining 11.9% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 45/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +814.8% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $1.49M↓ | $1.53M↑ | -$193,000↓ | $1.75M↑ | $1.37M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$16.44M↑ | -$17.84M↓ | -$17.00M↑ | -$17.63M↓ | -$13.79M |
| Net Income | -$24.88M↓ | -$19.18M↓ | -$17.71M↑ | -$20.05M↓ | -$14.74M |
Peer Comparison
JNJUNHPFE
Fundamentals
Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene thera...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$457.80M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
2.20
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
494.15%
Volume
Today's trading volume
2.78M
Recent News
OCGN Advances Gene Therapy OCU410 In Phase III for Geographic Atrophy
Ocugen moves OCU410 into phase III for geographic atrophy, with FDA-aligned study plans. The company expects to file a BLA for OCU410 in 2028.
Ocugen Targets 2027 BLA Filings as Gene Therapy Programs Near Key Readouts
Ocugen (NASDAQ:OCGN) is positioning its ophthalmology gene therapy portfolio around treatments for inherited retinal diseases and dry age-related macular degeneration, with pivotal-stage programs in retinitis pigmentosa, Stargardt disease and geographic atrophy, Chairman, CEO and Co-Founder Shankar
Ocugen (OCGN) Q2 2026 Earnings Call Transcript
Gene therapy developer advances three Phase III programs toward 2028 regulatory filings.
Ocugen's Q2 Earnings Miss Estimates as R&D Costs Rise, Stock Falls
OCGN posts a wider Q2 loss as R&D spending climbs, while advancing late-stage gene therapy programs and extending its cash runway into 2028.
Ocugen Q2 Earnings Call Highlights
Ocugen (NASDAQ:OCGN) said its second quarter marked progress across its late-stage ophthalmology pipeline, including FDA clearance to begin a Phase III study of OCU410 in geographic atrophy and an RMAT designation for the program. Chairman, Chief Executive Officer and Co-Founder Shankar Musunuri sa